Skip to Content

Brilinta (ticagrelor) Disease Interactions

There are 5 disease interactions with Brilinta (ticagrelor):


Ticagrelor (Includes Brilinta) ↔ bleeding

Severe Potential Hazard, High plausibility. Applies to: Bleeding, Peptic Ulcer

Ticagrelor is contraindicated in patients with active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.


Ticagrelor (Includes Brilinta) ↔ liver dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Ticagrelor is metabolized by the liver. The use of ticagrelor should be avoided in patients with severe hepatic impairment. Care should be taken in patients with moderate hepatic impairment and it is recommended to consider the risks and benefits of treatment due to the probable increase in exposure to ticagrelor. No dosage adjustment is needed in patients with mild hepatic impairment.


Ticagrelor (Includes Brilinta) ↔ bradyarrhythmias

Moderate Potential Hazard, Moderate plausibility. Applies to: Sinus Node Dysfunction

Ticagrelor can cause ventricular pauses. Bradyarrhythmias including AV block have been reported in the postmarketing setting. It is recommended to use care if prescribing this agent to patients with a history of sick sinus syndrome, 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker as they may be at increased risk of developing bradyarrhythmias.


Ticagrelor (Includes Brilinta) ↔ dyspnea

Moderate Potential Hazard, Moderate plausibility. Applies to: Pulmonary Impairment

Dyspnea has been reported with the use of ticagrelor. Care should be taken when prescribing this drug to patients that experienced dyspnea. If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to the drug, no specific treatment is required; continue treatment and monitoring without interruption, if possible. In the case of intolerable dyspnea requiring discontinuation, consider prescribing another antiplatelet agent.


Ticagrelor (Includes Brilinta) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: hemodialysis

No dosage adjustment is needed in patients with renal impairment. Patients receiving dialysis have not been studied, close monitoring is recommended.

Brilinta (ticagrelor) drug interactions

There are 549 drug interactions with Brilinta (ticagrelor)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.